New treatment options for chronic lymphocytic leukemia
作者： Julio Delgado , Tycho Baumann , Rodrigo Santacruz , Emili Montserrat
DOI: 10.1517/14656566.2014.891017
关键词:
摘要: Introduction: Chemoimmunotherapy is the gold standard of therapy for patients with advanced chronic lymphocytic leukemia (CLL), resulting in high and durable complete response rates. However, all eventually relapse CLL remains incurable. Newer more rationally developed compounds are needed to improve therapy, particularly cases refractory disease. Areas covered: Following a literature search on PubMed using ‘chronic’, ‘lymphocytic’, ‘treatment’ ‘therapy’ as keywords, results obtained novel agents were critically analyzed. Abstracts presented during 2013 at ASH, EHA, ICML, IWCLL ASCO meetings also included search. Expert opinion: New monoclonal antibodies, lenalidomide, B-cell receptor-signal transduction inhibitors pro-apoptotic molecules have shown efficacy relapsed or Hopefully, combined use these risk-adapted treatment strategies will outcome pave way...
researchgate.net 
sci-hub.se 参考文章(62)
Jan A. Burger, Michael J. Keating, William G. Wierda, Julia Hoellenriegel, Ghayathri Jeyakumar, Alessandra Ferrajoli, Stefan H. Faderl, Marylou Cardenas-Turanzas, Susan Lerner, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, Susan O'Brien, Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients Blood. ,vol. 122, pp. 675- 675 ,(2013) , 10.1182/BLOOD.V122.21.675.675
Peter Hillmen, Tadeusz Robak, Ann Janssens, K Govindbabu, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas Boyd, Marco Montillo, Astrid McKeown, Jodi L Carey, Ira V Gupta, Chai-Ni Chang, Steen Lisby, Fritz Offner, Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) Blood. ,vol. 122, pp. 528- 528 ,(2013) , 10.1182/BLOOD.V122.21.528.528
Mohammed Farooqui, Georg Aue, Janet Valdez, Sabrina Martyr, Jade Jones, Susan Soto, Maryalice Stetler-Stevenson, Constance Yuan, Diane C Arthur, Francine Thomas, Xin Tian, Delong Liu, Irina Maric, Adrian Wiestner, Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p Blood. ,vol. 122, pp. 673- 673 ,(2013) , 10.1182/BLOOD.V122.21.673.673
Inge Tinhofer, Ingrid Marschitz, Marion Kos, Traudl Henn, Alexander Egle, Andreas Villunger, Richard Greil, Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. ,vol. 91, pp. 4273- 4281 ,(1998) , 10.1182/BLOOD.V91.11.4273
Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Ling-Hua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George Muller, Peter Schafer, David Stirling, Angus G. Dalgleish, J. Blake Bartlett, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research. ,vol. 69, pp. 56- 63 ,(2005) , 10.1016/J.MVR.2005.01.002
M Le Garff-Tavernier, L Herbi, C de Romeuf, F Nguyen-Khac, F Davi, A Grelier, M Boudjoghra, K Maloum, S Choquet, R Urbain, V Vieillard, H Merle-Béral, Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. ,vol. 28, pp. 230- 233 ,(2014) , 10.1038/LEU.2013.240
Mark D. Danese, Robert I. Griffiths, Michelle Gleeson, Sacha Satram-Hoang, Kevin Knopf, Joseph Mikhael, Carolina Reyes, An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. ,vol. 117, pp. 3505- 3513 ,(2011) , 10.1182/BLOOD-2010-08-301929
Jonathan W. Friedberg, Jeff Sharman, John Sweetenham, Patrick B. Johnston, Julie M. Vose, Ann LaCasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P. Leonard, Larry D. Cripe, Stephanie A. Gregory, Michael P. Sterba, Ann M. Lowe, Ronald Levy, Margaret A. Shipp, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood. ,vol. 115, pp. 2578- 2585 ,(2010) , 10.1182/BLOOD-2009-08-236471
Adrian Wiestner, Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia Blood. ,vol. 120, pp. 4684- 4691 ,(2012) , 10.1182/BLOOD-2012-05-423194
William G. Wierda, Thomas J. Kipps, Jan Dürig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiří Mayer, Geoffrey Chan, Ira Gupta, Tina G. Nielsen, Charlotte A. Russell, **102 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia Clinical Lymphoma, Myeloma & Leukemia. ,vol. 11, ,(2011) , 10.1016/J.CLML.2011.05.003